Microbot Medical announces another step in its commitment to advance the commercialization processes of LIBERTY with the signing of a manufacturing agreement with B.Y. Medimor Ltd. The agreement governs the manufacturing of the Company’s LIBERTY Robotic Surgical System, for its first in human clinical trial as well as for the initial LIBERTY systems that are expected to be marketed following the completion of regulatory requirements. “We continue our transition from a research and development stage to a clinical and commercial stage in the field of endovascular robotics,” commented Simon Sharon, Microbot’s CTO and General Manager. “We believe that the manufacturing agreement supports our efforts to deliver a state-of-the-art advanced robotic system and facilitates our next steps.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MBOT:
- Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System
- Microbot Medical appoints Cornelis to scientific advisory board
- Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board
- Microbot Medical engages Notified Body to advance CE mark for Europe sales
- Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in Europe